NextCure, Inc.: Affinity Asset Advisors, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Affinity Asset Advisors, LLC amended its Schedule 13G filing on NextCure, Inc., updating its beneficial ownership stake with the SEC under accession number 0001011438-26-000697. The amendment signals a change in the investment firm's position in the clinical-stage biopharmaceutical company. The filing did not disclose the specific size of the stake or the direction of the change in the headline disclosure. Investors will watch for further detail on whether Affinity increased or reduced its holdings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Affinity Asset Advisors, LLC, NextCure, Inc.